

Research Article

Methylenetetrahydrofolate Reductase A1298C Polymorphism and Autism Susceptibility

Rai V* and Kumar P

Human Molecular Genetics Laboratory, Department of Biotechnology, VBS Purvanchal University, India

***Corresponding author:** Vandana Rai, Human Molecular Genetics Laboratory, Department of Biotechnology, VBS Purvanchal University, Jaunpur- 222 003, India**Received:** March 22, 2018; **Accepted:** May 09, 2018;**Published:** May 16, 2018**Abstract**

Background: Methylenetetrahydrofolate reductase (*MTHFR*) is a key enzyme involved in folate/homocysteine metabolism. A polymorphism A1298C has been reported to be linked with risk of several diseases/disorders like birth defects, metabolic and psychiatric disorders and different cancers. The association between autism and *MTHFR* gene A1298C polymorphism has been investigated in several case-control studies, which rendered contradictory results.

Aim: To shed light on association between *MTHFR* A1298C polymorphism and risk of autism, a meta-analysis of published case control association studies was conducted.

Methods: Four electronic databases: PubMed, Google Scholars, Elsevier and Springer Link were searched up to August, 2016. All statistical analyses were performed using MetaAnalyst and Mix (version 1.7). Odds ratios (ORs) with their 95% confidence intervals (95% CIs) were calculated. Total seven studies with 1,424 cases and 1,513 controls were included in the present meta-analysis.

Results: The results of meta-analysis suggested that there were no significant association between A1298C polymorphism and autism risk using overall comparisons in five genetic models (A vs C: OR=0.99, 95%CI=0.80-1.23, p=0.005; AC vs AA: OR = 1.04, 95% CI = 0.75-1.43, p = 0.82; CC vs AA: OR = 0.16, 95% CI = 0.06-0.45, p = 0.006; CC+AC vs AA: OR = 0.45, 95% CI = 0.25-0.80, p = 0.006; CC vs AC+AA: OR = 0.15, 95% CI = 0.06-0.37, p<0.0001). Publication bias was absent.

Conclusion: In conclusion, results of present meta-analysis showed no significant association between *MTHFR* A1298C polymorphism and autism risk.

Keywords: Autism; *MTHFR*; A1298C; Homocysteine

Introduction

Autism is a complex neurodevelopment disorder involving multiple organ systems, primarily immunological, gastrointestinal and neurological ones [1] and appears in the early years of life [2-4]. It is currently estimated that 3-6 children out of 1000 worldwide have autism spectrum disorder (ASD) [5]. The incidence of autism has increased rapidly in recent decades [6,7]. It is a heterogeneous neurological disorder characterized by three core behavior abnormalities-namely, deficits in social interaction, reduced verbal and nonverbal communication, and highly focused stereotyped behaviors that emerge after a period of relatively normal development [8]. A number of factors such as genetic, epigenetic, environmental and autoimmune function have been implicated in the etiology of autism [6,9-14].

One carbon (C1) metabolism is a likely pathway to regulate epigenetic processes in autism [15]. C1 metabolism is comprised of three interconnected pathways-folate cycle, methionine cycle and transsulfuration cycle. The folate and methionine pathway mediates de novo nucleotide synthesis for DNA repair and replication and DNA methylations. The transsulfuration pathway balance cellular redox.

There are several evidences that in autistic children, DNA methylation and DNA repair are altered [16,17] as well as dysregulation of redox homeostasis [18], which reinforces a critical role for C1 metabolism in the etiology of ASDs [15]. One carbon metabolic pathway include several genes and most of them are polymorphic especially methylenetetrahydrofolate reductase (*MTHFR*) and methionine synthase reductase (*MTRR*) and frequency of mutant alleles varies greatly worldwide [19-25].

Folate facilitates methionine synthesis from homocysteine by acting as a cofactor for methylene tetrahydrofolate reductase (*MTHFR*) which converts 5,10-methylenetetrahydrofolate (CH₂THF) to 5-methyltetrahydrofolate (CH₃THF). 5-methyltetrahydrofolate donates methyl group for the conversion of homocysteine in to methionine, which further converted in to S-adenosyl-methionine (SAM). SAM is universal methyl group donor, which transfer methyl to DNA, RNA, proteins, phospholipids, or neurotransmitters [26]. Consistently global DNA hypomethylation observed in autistic children [27-29]. Methyl deficiency may strongly impact epigenetic remodeling during key periods of development.

MTHFR gene is 20 kb long (20,336 bp) and mapped at 1p36.3




Figure 1: Random effect Forest plot of allele contrast model (C vs. A) of *MTHFR* A1298C polymorphism.

(OMIM 607093), having 11 exons. Several single nucleotide polymorphisms (SNPs) have been identified in *MTHFR* gene. Among which the most commonly studied polymorphisms are C677T in exon 4 and A1298C in exon 7 [30,31]. These two polymorphisms were shown to be associated with reduced enzyme activity and their frequency varies greatly in different geographical regions. The A1298C polymorphism codes for an alanine to glutamine substitution in the C-terminal regulatory domain [32]. Individuals homozygous for the A1298C have approximately the same enzyme activity as those heterozygous for C677T allele [32,33]. The prevalence of the A1298C homozygote variant genotype ranges from 7 to 12% in White populations from North America and Europe. Lower frequencies have been reported in Hispanics (4 to 5%), Chinese (1 to 4%) and Asian populations (1 to 4%) [34,35]. There are conflicting results about the role of *MTHFR* polymorphism A1298C as risk for autism. To derive a precise estimation of relationship between *MTHFR* A1298C polymorphism and autism risk, we conducted present meta-analysis.

Methods

Search strategy, identification of studies and data extraction

A literature search of the PubMed, Google Scholar, Science Direct, and Springer Link databases was conducted using combinations of the following terms: “polymorphism or variant or mutation” and “Autism” and “Methylenetetrahydrofolate reductase or *MTHFR*” and “A1298C”. Studies that were included in the present meta-analysis had to meet the following criteria: 1) study should evaluated *MTHFR* gene A1298C polymorphism in autism cases, 2) study should be a case-control, and 3) study should reported sufficient genotype/allele numbers for estimation of odds ratio (OR) with a 95% Confidence Interval (CI).

The following information was extracted from each included study: first author’s family name, journal name, year of publication, country name, number of cases and controls. Number of alleles or genotypes in both cases and controls were extracted or calculated from published data to recalculate ORs.

Meta-analysis

Crude odds ratio with 95% CI were used to assess strength of association between *MTHFR* A1298C genotypes and risk of autism in log additive/ allele contrast (C vs A), homozygote (CC vs AA), co-dominant/heterozygote (AC vs AA), dominant (CC+AC vs AA) and recessive (CC vs AC+AA) models. The statistical significance of the




Figure 2: Funnel plots of precision by OR of *MTHFR* A1298C allele contrast model (C vs. A).

pooled OR was determined using a Z test and $p < 0.05$ was considered statistically significant.

The heterogeneity of these studies was tested by the Q statistic and was considered statistically significant when $p < 0.05$ [36]. The pooled OR was estimated using the fixed effects model when there was less heterogeneity [37], or random effects model when there was higher heterogeneity [38]. All included studies were tested for genotypic distribution of the *MTHFR* A1298C polymorphism in the control group with the HWE principle using the χ^2 -test.

Funnel plots were used to detect publication bias. However, due to the limitations of funnel plotting, which require a range of studies of varying sizes involving subjective judgments, publication bias was evaluated using Egger’s linear regression test [40]. All p-values are two tailed with a significance level at 0.05. All statistical analyses were undertaken by MetaAnalyst [41] and MIX version 1.7 [42].

Results

Characteristics of included studies

Seven relevant studies describing the association between *MTHFR* A1298C and autism were identified [41-47] (Table 1). However, in the study of Mohammad et al. [43], the distributions of genotypes in the control groups were not in HWE ($p < 0.05$), indicating genotyping errors and/or population stratification. Except one study [45], six studies were on Caucasians. All the included studies were case-controlled, comprising 1,424 cases and 1,513 controls. In case groups, the frequencies of AA-homozygote, AC heterozygote and CC homozygote were 51.39%, 38.88% and 9.729% respectively. In control groups, the frequencies of AA homozygote, AC-heterozygote, and CC-homozygote were 52.46, 37.02 and 10.51%, respectively. The C allele frequencies in the case and control groups were 29.55 and 29.11%, respectively (Figure 1).

Meta-analysis

The results of present meta-analysis exhibited high heterogeneity in several genetic models when all eligible studies were pooled together (Table 2). Thus, random effect model was applied to calculate the OR.

Table 1: Distribution of different *MTHFR* genotypes in seven included meta-analysis.

Study	Population	Case/Control	Case genotype			Control Genotype			HWE P- value
			AA	AC	CC	AA	AC	CC	
Boris et al.,2004	Caucasian	168/159	93	65	10	70	75	14	0.33
James et al.,2006	Caucasian	356/204	175	147	34	103	77	24	0.10
Mohammad et al.,2009	Asian	138/138	35	59	44	48	32	58	0.00
Liu et al.,2011	Caucasian	205/382	109	81	15	170	175	37	0.40
Schmidt et al.,2011	Caucasian	296/177	160	117	19	89	76	12	0.43
Park et al., 2014	Caucasian	236/423	147	75	14	298	114	11	0.98
Meguid et al.,2015	Caucasian	24/30	0	23	1	12	16	2	0.27

Table 2: Summary estimates for the odds ratio (OR) of *MTHFR* A1298C in various allele/genotype contrasts, the significance level (p value) of heterogeneity test (Q test), and the I² metric and publication bias p-value (Egger Test).

Genetic Models	Fixed effect OR (95% CI), p	Random effect OR (95% CI), p	Heterogeneity p-value (Q test)	I ² (%)	Publication Bias (p of Egger's test)
All studies (32)					
Allele Contrast (C vs A)	0.95 (0.84-1.07), 0.4	0.99(0.80-1.23),0.0051	0.01	64.81	0.74
Co-dominant (AC vs AA)	1.001(0.85-1.17),0.9	1.04(0.75-1.43),0.82	0.001	73.67	0.39
Homozygote (CC vs AA)	0.13(0.10-0.15),<0.0001	0.16(0.06-0.45),0.0006	<0.0001	94.87	0.3
Dominant (CC+ AC vs AA)	0.44(0.37-0.50),<0.0001	0.45(0.25-0.80),0.006	<0.0001	93.62	0.67
Recessive (CC vs AC+AA)	0.12(0.1-0.14),<0.0001	0.15(0.06-0.37),<0.0001	<0.0001	94.15	0.34

The results indicated that *MTHFR* A1298C polymorphism was not associated with autism risk (allele contrast A vs C: OR=0.99, 95% CI=0.80-1.23, p=0.005; the heterozygote model AC vs AA: OR = 1.04, 95% CI = 0.75-1.43, p = 0.82; the homozygous model CC vs AA: OR = 0.16, 95% CI = 0.06-0.45, p = 0.006; the dominant model CC+AC vs AA: OR = 0.45, 95% CI = 0.25-0.80, p = 0.006; and recessive model CC vs AC+AA: OR = 0.15, 95% CI = 0.06-0.37, p<0.0001). In order to derive a more precise result and to clarify the heterogeneity among studies, author conducted a subgroup meta-analysis stratified with the ethnicity. Six studies were from Caucasian population and only one study was from Asian population, so sub group analysis was performed only on Caucasian studies only. In this subgroup analysis, no significant association between *MTHFR* A1298C polymorphism and autism susceptibility was found in Caucasian population.

Publication bias

The shape of the funnel plots showed that the dots were almost symmetrically distributed and were predominantly in 95% confidence limits (dominant model, Figure 2). The results of Egger's test statistically confirmed the absence of publication bias in the dominant model (p= 0.67).

Discussion

Normal activity of *MTHFR* is required for normal genome methylation and imprinting. The DNA methylation or epigenetic programming is essential for gene imprinting and cell differentiation during embryogenesis [48]. Most critical period of epigenetic programming are prenatal and early post natal, when DNA methylation is essential for development of normal brain and neuron networks [15]. Genetic, epigenetic and environment factors play important role in autism rate and symptom severity [15].

The epigenetic mechanism controls several processes during

neurodevelopment which occurs prenatally and early postnatal up to 2 years of age like (i) establishment of neuron networks, (ii) selected cell death, (iii) synaptogenesis and (iv).

Pruning of inappropriate dendritic arbors and synapses etc. High concentration of Hcy and its metabolites inhibit activity of methyl transferases like Catechol-O-methyl transferase (COMT) [49]. And experiments on animal models have showed that COMT activity is high during early embryogenesis at the time of development of sympathetic nervous system [50]. COMT degrades dopamine neurotransmitter by transferring methyl group from SAM to dopamine. Excess dopamine inhibits expression of brain derived neurotrophic factor (BDNF) [51], which is essential for normal brain development [45]. Abnormal methylation due to variant *MTHFR* enzyme reduced the activity of COMT and increased the concentration of dopamine, which consequently inhibit the synthesis of BDNF and abnormal neurodevelopment is resulted [51].

Meta-analysis is an acceptable useful methodology suitable for elucidating genetic factors in different diseases/disorders. Several meta-analysis were published which evaluated risk of folate pathway genes polymorphism for different disease and disorders- like Down syndrome [52-54], orofacial clefts [55,56], recurrent pregnancy loss [57,58], male infertility [59], schizophrenia [60,61], depression [62], autism [63], Alzheimer's disease [64], breast cancer [65,66], prostate cancer [67], colorectal cancer [68] and ovary cancer [69] etc.

Certain limitations exist in the meta-analysis- (i) present meta-analysis based on unadjusted data, (ii) only seven studies and small sample size (2936) limited the ability to draw more solid conclusions, (iii) there is marked heterogeneity among studies, (iv) although the Egger's test did not show any publication bias, selection bias could have occurred, because only published studies were included in present meta-analysis, (vi) interactions between gene-gene and gene-

environment could not be included in present meta-analysis due to a lack of relative data and (vii) only four databases were searched, so it might be possible that few relevant studies were left.

Results of present meta-analysis suggested that A1298C polymorphism of *MTHFR* gene was not a risk factor for autism susceptibility in overall population as well as, in Caucasian populations. Large studies that assess the interrelations between folate intake and *MTHFR* polymorphism are needed to further clarify the role of *MTHFR* polymorphism in the development of autism.

References

- Kałużna-Czaplińska J, Michalska M, Rynkowski J. Homocysteine level in urine of autistic and healthy children. *Acta Biochemica Polonica*. 2011; 58: 31-34.
- Santangelo SL, Tsatsanis K. What is known about autism: genes, brain, and behavior? *Am J Pharmacogenomics*. 2005; 5: 71-92.
- Keller F, Persico AM. The neurobiological context of autism. *Mol Neurobiol*. 2007; 28: 1-22.
- Blaylock RL. A possible central mechanism in autism spectrum disorders, part 1. *Altern Ther Health Med*. 2008; 14: 46-53.
- Shawky RM, El-baz F, T Kamal TM, Elhossiny RM, Ahmed MA, El Nady GH. Study of genotype-phenotype correlation of methylene tetrahydrofolate reductase (*MTHFR*) gene polymorphisms in a sample of Egyptian autistic children. *The Egyptian Journal of Medical Human Genetics*. 2014; 15: 335-341.
- Weiser M, Reichenberg A, Werbeloff N, Kleinhaus K, Lubin G, Shmushkevitch M, et al. Advanced parental age at birth is associated with poorer social functioning in adolescent males: shedding light on a core symptom of schizophrenia and autism. *Schizophr Bull*. 2008; 34: 1042-1046.
- Towle PO, Visintainer PF, O'Sullivan C, Bryant NE, Busby S. Detecting autism spectrum disorder from early intervention charts: methodology and preliminary findings. *J Autism Dev Disord*. 2009; 39: 444-452.
- American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, American Psychiatric Press, Washington, DC, USA, 5th edition, 2013.
- Reading R. Autism spectrum disorders: clinical and research frontiers. *Child Care Health Dev*. 2008; 34: 697-708.
- Ali A, Waly MI, Al-Farsi YM, Essa MM, Marwan M, Al-Sharbaty MM, et al. Hyperhomocysteinemia among Omani autistic children: a case-control study. *Acta Biochemica Polonica*. 2011; 58: 547-551.
- Bailey A, Le Couteur A, Gottesman I, Bolton P, Simonoff E. Autism as a strongly genetic disorder: Evidence from a British twin study. *Psychological Medicine*. 1995; 25: 63-77.
- Rai V. Autism Susceptibility Genes Identification by Linkage Analysis: A Review. *Int J Hum Genet*. 2010; 10: 207-216.
- Rai V. Autism Genetics and Cytogenetic Abnormalities. *Trends in Molecular Sciences*. 2011; 3: 1-13.
- Rai V. Autism Genetics: Recent Advances in Candidate Gene Search. *International Journal of Genetic Engineering and Biotechnology*. 2011; 2: 47-66.
- Schaevitz LR, Berger-Sweeney JE. Gene-Environment Interactions and Epigenetic Pathways in Autism: The Importance of One-Carbon Metabolism. *ILAR J*. 2012; 53: 322-340.
- Anagnostou E, Taylor MJ. Review of neuroimaging in autism spectrum disorders: What have we learned and where we go from here. *Mol Autism*. 2011; 2: 4.
- Schumann CM, Nordahl CW. Bridging the gap between MRI and postmortem research in autism. *Brain Res*. 2011; 1380: 175-186.
- Villagonzalo KA, Dodd S, Dean O, Gray K, Tonge B, Berk M. Oxidative pathways as a drug target for the treatment of autism. *Expert Opin Ther Targets*. 2010; 14: 1301-1310.
- Pepe G, Venegas OC, Giusti B, Brunelli T, Marcucci R, Attanasio M, et al. Heterogeneity in world distribution of thermolabile C677T mutation in 5,10-methylenetetrahydrofolate reductase. *Am J Hum Genet*. 1998; 63: 917-920.
- Rady PL, Szucs S, Grady J, Hudnall SD, Kellner LH, Nitowsky H, et al. Genetic polymorphisms of methylenetetrahydrofolate reductase (*MTHFR*) and methionine synthase reductase (MTRR) in ethnic populations in Texas; a report of a novel *MTHFR* polymorphic site, G1793A. *Am J Med Genet*. 2002; 107: 162-168.
- Rai V, Yadav U, Kumar P, Yadav SK. Prevalence of Methylenetetrahydrofolate reductase polymorphism (C677T) in Muslim population of Eastern Uttar Pradesh. *Indian J Hum Genet*. 2012; 18: 43-46.
- Rai V, Yadav U, Kumar P. Prevalence of methylenetetrahydrofolate reductase C677T polymorphism in eastern Uttar Pradesh. *Indian J Hum Genet*. 2012; 18: 43-46.
- Rai V, Yadav U, Kumar P. Genotype Prevalence and Allele Frequencies of 5,10-Methylenetetrahydrofolate Reductase (*MTHFR*) C677T Mutation in two Caste Groups of India. *Cell Mol Biol*. 2012; 58: OL1695-1701.
- Rai V, Yadav U, Kumar P, Yadav SK. Analysis of methionine synthase reductase polymorphism (A66G) in Indian Muslim Population. *Indian J Hum Genet*. 2013; 19: 183-187.
- Yadav U, Kumar P, Gupta S, Rai V. Distribution of *MTHFR* C677T gene polymorphism in healthy North Indian population and an updated meta-analysis. *Ind J Clinical Biochem*. 2017; 32: 399-410.
- Crooks PA, Tribé MJ, Pinney RJ. Inhibition of bacterial DNA cytosine-5-methyltransferase by S-adenosyl-L-homocysteine and some related compounds. *J Pharm Pharmacol*. 1984; 36: 85-89.
- Adams JB, Audhya T, McDonough-Means S, Rubin RA, Quig D, Geis E, et al. Nutritional and metabolic status of children with autism vs. neurotypical children, and the association with autism severity. *Nutr Metab (Lond)*. 2011; 8: 34.
- James SJ, Cutler P, Melnyk S, Jernigan S, Janak L, Gaylor DW, et al. Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. *Am J Clin Nutr*. 2004; 80: 1611-1617.
- Melnyk S, Fuchs GJ, Schulz E, Lopez M, Kahler SG, Fussell JJ, et al. Metabolic imbalance associated with methylation dysregulation and oxidative damage in children with autism. *J Autism Dev Disord*. 2012; 42: 367-377.
- Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. *Nat Genet*. 1995; 10: 111-113.
- Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (*MTHFR*) associated with decreased enzyme activity. *Mol Genet Metab*. 1998; 64: 169-172.
- Weisberg IS, Jacques PF, Selhub J, Boston Ag, Chen ZT, Ellison RC, et al. The 1298 A-C polymorphism in methylenetetrahydrofolate reductase (*MTHFR*): in vitro expression and association with homocysteine. *Atherosclerosis*. 2001; 156: 409-415.
- Botto LD, Yang Q. 5, 10-methylenetetrahydrofolate reductase variants and congenital anomalies: A huge review. *Am J Epidemiol*. 2000; 151: 862-877.
- Robien K, Ulrich CM. 5,10- Methylenetetrahydrofolate reductase polymorphisms and leukemia risk: a HuGe minireview. *Am J Epidemiol*. 2003; 157: 571-582.
- Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med*. 2002; 21: 1539-1558.
- Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. *J Natl Cancer Inst*. 1959; 22: 719-748.
- DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials*. 1986; 7: 177-188.

38. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *British Medical Journal*. 1997; 315: 629-634.
39. Wallace BC, Dahabreh IJ, Trikalinos TA, Lau J, Trow P, Schmid CH. Closing the Gap Between Methodologists and End-Users: R as a Computational Back-end. *J Stat Software*. 2012; 49: 1-15.
40. Bax L, Yu LM, Ikeda N, Tsuruta H, Moons KG. Development and validation of MIX: comprehensive free software for meta-analysis of causal research data. *BMC Med Res Methodol*. 2006; 6: 50.
41. Boris M, Goldblatt A, Galanko J, James J. Association of *MTHFR* gene variants with autism. *Journal of American Physicians and Surgeons*. 2004; 9: 106-108.
42. James SJ, Melnyk S, Jernigan S, Cleves MA, Halsted CH, Wong DH, et al. Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism. *Am J Med Genet B Neuropsychiatr Genet*. 2006; 141B: 947-956.
43. Mohammad NS, Jain JM, Chintakindi KP, Singh RP, Naik U, Akella RR. Aberrations in folate metabolic pathway and altered susceptibility to autism. *Psychiatr Genet*. 2009; 19: 171-176.
44. Liu X, Solehdin F, Cohen IL, Gonzalez MG, Jenkins EC, Lewis ME, et al. Population- and family-based studies associate the *MTHFR* gene with idiopathic autism in simplex families. *J Autism Dev Disord*. 2011; 41: 938-944.
45. Schmidt RJ, Hansen RL, Hartiala J, Allayee H, Schmidt LC, Tancredi DJ, et al. Prenatal vitamins, one-carbon metabolism gene variants, and risk for autism. *Epidemiology*. 2011; 22: 476-485.
46. Park JW, Ro MJ, Pyun JA, Kwack K, Nam M, Bang HJ, Yang JW, et al. *MTHFR* 1298A>C is a risk factor for autism spectrum disorder in the Korean population. *Psychiatry Res*. 2014; 215: 258-259.
47. Meguid N, Khalil R, Gebril O, El-Fishawy P. Evaluation of *MTHFR* Genetic Polymorphism as a Risk Factor in Egyptian Autistic Children and Mothers. *J Psychiatry*. 2015; 18: 1.
48. Li E. Chromatin modification and epigenetic reprogramming in mammalian development. *Nat Rev Genet* 2002; 3: 662-673.
49. Schatz RA, Wilens TE, Sellinger OZ. Decreased transmethylation of biogenic amines after in vivo elevation of brain S-adenosyl-L-homocysteine. *J Neurochem*. 1981; 36: 1739-1748.
50. Ignarro LJ, Shideman FE. Catechol-O-methyl transferase and monoamine oxidase activities in the heart and liver of the embryonic and developing chick. *J Pharmacol Exp Ther*. 1968; 159: 29-37.
51. Fumagalli F, Racagni G, Colombo E, Riva MA. BDNF gene expression is reduced in the frontal cortex of dopamine transporter knockout mice. *Mol Psychiatry*. 2003; 8: 898-899.
52. Rai V. Polymorphism in folate metabolic pathway gene as maternal risk factor for Down syndrome. *Int J Biol Med Res*. 2011; 2: 1055-1060.
53. Rai V, Yadva U, Kumar P. Null association of maternal *MTHFR* A1298C polymorphism with Down syndrome pregnancy: An updated meta-analysis. *Egyptian Journal of Medical Human Genetics*. 2017; 18: 9-18.
54. Rai V, Kumar P. Fetal *MTHFR* C677T polymorphism confers no susceptibility to Down Syndrome: evidence from meta-analysis. *Egyptian J Med Hum Genet*. 2018; 19: 53-58.
55. Rai V. Maternal methylenetetrahydrofolate reductase (*MTHFR*) gene A1298C polymorphism and risk of nonsyndromic Cleft lip and/or Palate (NSCL/P) in offspring: A meta-analysis. *Asian Journal of Medical Sciences*. 2015; 6: 16-21.
56. Rai V. Strong association of C677T polymorphism of ethylenetetrahydrofolate reductase gene with no syndromic cleft lip/palate (nsCL/P). *Ind J Clin Biochem*. 2017; 1-11.
57. Rai V. Methylenetetrahydrofolate reductase gene A1298C polymorphism and susceptibility to recurrent pregnancy loss: a meta-analysis. *Cell Mol Biol*. 2014; 60: 27-34.
58. Rai V. Methylenetetrahydrofolate reductase C677T polymorphism and recurrent pregnancy loss risk in Asian population: a meta-analysis. *Indian J Clin Biochem*. 2016; 31: 402-413.
59. Rai V, Kumar P. Methylenetetrahydrofolate reductase C677T polymorphism and risk of male infertility in Asian population. *Ind J Clin Biochem*. 2017; 32: 253-260.
60. Yadav U, Kumar P, Gupta S, Rai V. Role of *MTHFR*C677T gene polymorphism in the susceptibility of schizophrenia: An updated meta-analysis. *Asian J Psychiatry*. 2016; 20: 41-51.
61. Rai V, Yadav U, Kumar P, Yadav SK, Gupta S. Methylenetetrahydrofolate Reductase A1298C Genetic Variant and Risk of Schizophrenia: an updated meta-analysis. *Indian J Med Res*. 2017; 145: 437-447.
62. Rai V. Genetic polymorphisms of methylenetetrahydrofolate reductase (*MTHFR*) gene and susceptibility to depression in Asian population: a systematic meta-analysis. *Cell Mol Biol*. 2014; 60: 29-36.
63. Rai V. Association of methylenetetrahydrofolate reductase (*MTHFR*) gene C677T polymorphism with autism: evidence of genetic susceptibility. *Metab Brain Dis*. 2016; 31: 727-735.
64. Rai V. Folate pathway gene methylenetetrahydrofolate reductase C677T polymorphism and Alzheimer disease risk in Asian population. *Indian J Clin Biochem*. 2016; 31: 245-252.
65. Rai V. Methylenetetrahydrofolate Reductase A1298C Polymorphism and Breast Cancer Risk: A Meta-analysis of 33 Studies. *Ann Med Health Sci Res*. 2014; 4: 841-851.
66. Kumar P, Yadav U, Rai V. Methylenetetrahydrofolate reductase gene C677T polymorphism and breast cancer risk: Evidence for genetic susceptibility. *MetaGene*. 2015; 6: 72-84.
67. Yadav U, Kumar P, Rai V. Role of *MTHFR* A1298C gene polymorphism in the etiology of prostate cancer: A systematic review and updated meta-analysis. *Egyptian Journal of Medical Human Genetics*. 2015; 17: 141-148.
68. Rai V. Evaluation of the *MTHFR* C677T Polymorphism as a Risk Factor for Colorectal Cancer in Asian Populations. *Asian Pac J Cancer Prev*. 2016; 16: 8093-8100.
69. Rai V. Methylenetetrahydrofolate Reductase Gene C677T Polymorphism and Its Association with Ovary Cancer. *J Health Med Informat*. 2016; 7: 3.